Kerala scientific body backs generic drug push for SMA patients

The Kerala Sastra Sahitya Parishad (KSSP), a prominent scientific and cultural organization in the state, has thrown its weight behind efforts to expand access to generic drugs for patients suffering from spinal muscular atrophy (SMA). The advocacy comes as the organization seeks to ensure that cost remains no barrier to treatment for the degenerative neurological condition.

KSSP President C. Ramakrishnan and General Secretary V. Manoj Kumar underscored the critical role that affordable medications play in enhancing both the quality of life and life expectancy for SMA patients. The organization's position reflects growing concerns about drug accessibility in Kerala and across India, where expensive branded pharmaceuticals often remain beyond the reach of ordinary families.

Spinal muscular atrophy is a rare genetic disorder characterized by progressive muscle weakness and degeneration. While treatment options have expanded in recent years, the high cost of proprietary medications has limited their availability to patients from economically disadvantaged backgrounds. The push for generic alternatives aims to democratize access to these potentially life-altering therapies.

The KSSP's intervention adds institutional credibility to a broader public health debate about pharmaceutical pricing and equitable healthcare access in Kerala. The organization's advocacy may influence policy discussions around drug approvals and pricing regulations within the state health system.